SG Americas Securities LLC Decreases Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

SG Americas Securities LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 76.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,069 shares of the company's stock after selling 99,223 shares during the period. SG Americas Securities LLC's holdings in Arcus Biosciences were worth $460,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Point72 DIFC Ltd bought a new position in Arcus Biosciences in the 2nd quarter valued at approximately $83,000. Algert Global LLC lifted its holdings in shares of Arcus Biosciences by 30.9% during the second quarter. Algert Global LLC now owns 76,257 shares of the company's stock valued at $1,161,000 after purchasing an additional 17,999 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Arcus Biosciences by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company's stock valued at $455,000 after purchasing an additional 2,123 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Arcus Biosciences by 67.9% during the second quarter. AQR Capital Management LLC now owns 24,524 shares of the company's stock valued at $374,000 after buying an additional 9,916 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Arcus Biosciences in the 2nd quarter worth about $406,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on RCUS shares. Cantor Fitzgerald restated an "overweight" rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Wedbush restated an "outperform" rating and set a $30.00 price objective on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $29.00 target price for the company. Barclays lowered their price target on Arcus Biosciences from $35.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, July 8th. Finally, Evercore ISI raised Arcus Biosciences to a "strong-buy" rating in a report on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $34.88.

Arcus Biosciences Trading Up 2.1 %

Arcus Biosciences stock traded up $0.38 during trading on Thursday, reaching $18.24. The company had a trading volume of 926,009 shares, compared to its average volume of 717,449. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -5.86 and a beta of 0.88. The firm's 50-day simple moving average is $16.67 and its 200 day simple moving average is $16.06. Arcus Biosciences, Inc. has a 52 week low of $12.95 and a 52 week high of $20.31.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, hitting the consensus estimate of ($1.02). The firm had revenue of $39.00 million for the quarter, compared to the consensus estimate of $26.24 million. Arcus Biosciences had a negative return on equity of 42.86% and a negative net margin of 100.81%. The business's revenue for the quarter was up 34.5% compared to the same quarter last year. During the same quarter last year, the company earned ($1.04) earnings per share. On average, analysts predict that Arcus Biosciences, Inc. will post -3.03 earnings per share for the current year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.